| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.028 | 0.8 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.071 | 0.8 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |